- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00975065
Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus
August 21, 2012 updated by: Handok Inc.
A 24-week, Open-label, Randomized, Multi-center, Parallel-group Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Prior Metformin Monotherapy in Comparison to up Titrating Metformin Dose.
The study design of this trial is open-label, randomized, multi-center, parallel-group study.
Study Overview
Status
Completed
Conditions
Detailed Description
- The progressive nature of T2DM will require the use of combination therapy in many patients over time to achieve and maintain glycemic control. Early combination, compared with maximal dose of monotherapy, could be more effective in lowering glycemia with better tolerability.
- Vildagliptin is a new oral antidiabetic drug acting as a potent and selective inhibitor of dipeptidyl peptidase-4(DPP-4), the enzyme responsible for the rapid degradation of circulating glucagon-like peptide-1. Vildagliptin improves islet function by a mechanism of increasing plasma levels of the active forms of the incretin hormones, GLP-1 and GIP.
- Metformin improves hyperglycemia primarily through its suppression of hepatic gluconeogenesis as well as enhancement of peripheral glucose update. Metformin is the most commonly prescribed first-line antidiabetic drug worldwide, but due to the progressive worsening of blood glucose control during the natural history of type 2 diabetes, combination therapy usually becomes necessary.
- Thus their combination therapy with complimentary action mechanism could be as effective as up titration of monotherapy.
Study Type
Interventional
Enrollment (Actual)
266
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Handok Pharmaceuticals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with Type 2 Diabetes Mellitus who were inadequately controlled (baseline A1c of 7.0~11.0%)on metformin monotherapy (1500mg metformin)for ≥ 2 months before baseline visit
- Age of 18-80 years
- Body Mass Index of 18-40 kg/m2
Exclusion Criteria:
- Type 1 of diabetes
- Myocardial Infarction, Unstable Angina, or Coronary Artery Bypass Graft within the previous 6 months
- Congestive Heart Failure (III or NYHA class IV)
- Liver disease such as cirrhosis or Chronic Active Hepatitis
- History of Lacticacidemia
- Use of any Oral Anti-diabetic Drug other than Metformin within the 2 months
- Use of insulin before screening visit
- ALT or AST >3 times the upper limit of Normal range
- Creatinine >1.5 mg/dl
- Other situation (pregnant or lactating females, history of drug or alcohol abuse, night-shift workers, clinically significant laboratory abnormality on screening or any medical condition that would affect the completion or outcome of the study)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Galvus group
the combination of metformin plus Vildagliptin:
|
vildagliptin 50 mg bid plus metformin 1500mg
|
ACTIVE_COMPARATOR: Diabex group
metformin alone arm:
|
metformin 1500mg plus metformin 500mg or 1000mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hemoglobin A1c at 24 weeks
Time Frame: 32weeks
|
32weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hemoglobin A1c at 12 weeks
Time Frame: 32weeks
|
32weeks
|
Fasting plasma glucose(Self Monitored Blood Glucose) at 24 week
Time Frame: 32weeks
|
32weeks
|
2hours post-prandial plasma glucose(Self Monitored Blood Glucose) at 24 week
Time Frame: 32weeks
|
32weeks
|
Fasting Lipid profiles at 24 week
Time Frame: 32weeks
|
32weeks
|
Body weight at 24 week
Time Frame: 32weeks
|
32weeks
|
Hypoglycemic events, Gastro-Intestinal events, other adverse events at each visit
Time Frame: 32weeks
|
32weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sei Hyun Baik, professor, Korea University Guro Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (ACTUAL)
December 1, 2011
Study Completion (ACTUAL)
April 1, 2012
Study Registration Dates
First Submitted
September 9, 2009
First Submitted That Met QC Criteria
September 10, 2009
First Posted (ESTIMATE)
September 11, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
August 23, 2012
Last Update Submitted That Met QC Criteria
August 21, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Metformin
- Vildagliptin
Other Study ID Numbers
- CLAF237AKR03T
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)
-
Laboratorios Silanes S.A. de C.V.Recruiting
-
Merck Sharp & Dohme LLCCompleted
-
Damanhour UniversityTanta UniversityCompletedCoronary Artery Disease | Diabetes Mellitus, Type 2Egypt
-
NovartisCompleted
-
Reseach Laboratory of Clinical and Experimental...La Société Arabe des Industries Pharmaceutiques-Tunisie; Centre National Chalbi...Completed
-
Reseach Laboratory of Clinical and Experimental...Société Arabe des Industries Pharmaceutiques SAIPH - Tunisia; Centre National...CompletedFed ConditionsTunisia
-
International Bio serviceNot yet recruiting
-
University of CataniaCompletedMild Cognitive Impairment
-
MTI UniversityCompletedReducing the Elevated Blood Pressure for Diabetic Hypertensive PatientsEgypt
-
October 6 UniversityRecruitingPoly Cystic Ovary SyndromeEgypt